The value of the combination therapy of atorvastatin and ezetimibe in the treatment of coronary heart disease
阿托伐他汀与依折麦布联合用药在冠心病治疗中的价值研究

摘要

目的 探析阿托伐他汀+依折麦布在冠心病治疗中的效果。方法 回顾性分析2025年1月-2025年12月期间，院内62例冠心病患者病历资料。2025年1月-2025年6月的31例患者作为对照组（阿托伐他汀）。2025年7月-2025年12月的31例患者作为观察组（阿托伐他汀+依折麦布）。对比两组疗效。结果 治疗前两组对比，P>0.05。观察组左心室射血分数高于对照组，左心室舒张末期直径、左室收缩内径低于对照组，P<0.05。观察组高密度脂蛋白胆固醇水平高于对照组，总胆固醇及低密度脂蛋白胆固醇低于对照组，P<0.05。两组不良反应发生率对比，P>0.05。结论 阿托伐他汀联合依折麦布可显著改善患者心功能状态及血脂水平，且不会使得患者出现过多的不良反应，值得推广与应用。

Abstract

Objective To explore the effects of atorvastatin combined with ezetimibe in the treatment of coronary heart disease.
Methods A retrospective analysis was conducted on the medical records of 62 patients with coronary heart disease in the hospital from January 2025 to December 2025. Thirty-one patients from January to June 2025 were used as the control group (atorvastatin). Thirty-one patients from July to December 2025 were used as the observation group (atorvastatin combined with ezetimibe). The therapeutic effects of the two groups were compared.
Results The observation group had a higher left ventricular ejection fraction and lower left ventricular end-diastolic diameter and left ventricular interna systolic diameter than the control group (P<0.05). The observation group had higher levels of high-density lipoprotein cholesterol and lower levels of total cholesterol and low-density lipoprotein cholesterol than the control group (P<0.05). The incidence of adverse reactions in the two groups showed no significant difference (P>0.05).
Conclusion   Atorvastatin combined with ezetimibe can significantly improve cardiac function and blood lipid levels in patients, without causing excessive adverse reactions, and is worthy of promotion and application.